To cite: McCrae CS, Curtis AF, Craggs J, et al. Protocol for the impact of CBT for insomnia on pain symptoms and central sensitisation in fibromyalgia: a randomised controlled trial. BMJ Open 2020;10:e033760. doi:10.1136/bmjopen-2019-033760

ABSTRACT

Introduction Approximately 50% of individuals with fibromyalgia (a chronic widespread pain condition) have comorbid insomnia. Treatment for these comorbid cases typically target pain, but growing research supports direct interventions for insomnia (eg, cognitive behavioural treatment for insomnia (CBT-I)) in these patients. Previous research suggests sustained hyperarousal mediated by a neural central sensitisation mechanism may underlie insomnia and chronic pain symptoms in fibromyalgia. We hypothesise CBT-I will improve insomnia symptoms, improve clinical pain and reduce central sensitisation. The trial will be the first to evaluate the short-term and long-term neural mechanisms underlying insomnia and pain improvements in fibromyalgia. Knowledge obtained from this trial might allow us to develop new or modify current treatments to better target pain mechanisms, perhaps reversing chronic pain or preventing it.

Methods and analysis Female participants (n=130) 18 years of age and older with comorbid fibromyalgia (with pain severity of at least 50/100) and insomnia will be recruited from the University of Missouri in Columbia, Missouri, and surrounding areas. Participants will be randomised to 6 weeks (plus 4 bimonthly booster sessions) of CBT-I or a sleep hygiene control group (SH). Participants will be assessed at baseline, post-treatment, 6 and 12 months follow-ups. The following assessments will be completed: 2 weeks of daily diaries measuring sleep and pain, daily actigraphy, insomnia severity index, pain-related disability, single night of polysomnography recording, arousal (heart rate variability, cognitive affective arousal), structural and functional MRI to examine pain-related neural activity and plasticity and mood (depression, anxiety).

Ethics and dissemination Ethics approval was obtained in July 2018 from the University of Missouri. All data are expected to be collected by 2022. Full trial results are planned to be published by 2024. Secondary analyses of baseline data will be subsequently published.

Trial registration number NCT03744156.

INTRODUCTION

Background Chronic pain imposes a substantial public health burden, afflicting over 100 million Americans, with annual costs estimated at over US$500 billion.1 Individuals with chronic pain consume more healthcare services, yet 40% report inadequate management of their pain.2 Chronic insomnia (at least 3 months of difficulty initiating and/or maintaining sleep or early morning awakening, accompanied by dysfunction in at least one area of daytime functioning such as social, occupational, educational, academic, behavioural, etc)3 is highly comorbid with pain, affecting at least 50% of patients with chronic pain.3 Recent
research suggests chronic insomnia can lead to the development or worsening of chronic pain. Thus, research efforts to prevent, and treat chronic pain should consider sleep disturbance as a primary intervention target.

The relationship between fibromyalgia (a chronic condition characterised by widespread pain) and sleep disturbance is well established. Research on fibromyalgia has linked reports of restful sleep with less reported discomfort and fatigue, and non- restorative sleep with exacerbation of pain. Polysomnographic studies have identified sleep architecture differences in patients with fibromyalgia versus healthy controls (ie, increased sleep onset latency (SOL), lighter sleep, more arousals, reduced deep sleep. More than 50% of persons with fibromyalgia meet insomnia criteria, and fibromyalgia diagnostic criteria were recently revised to include sleep disturbance as a core feature. The causal role of sleep in the aetiology of chronic pain has gained empirical support. Longitudinal, experimental and trial evidence over the past decade suggest sleep may be a more reliable predictor of chronic pain, than vice versa. When chronic pain and insomnia co- occur, treatment typically focuses on pain. The insomnia is considered a symptom and thus, is expected to improve following improvement in pain. However, a growing body of research, including our recent trial, supports direct intervention for insomnia in the context of pain.

Fibromyalgia is characterised by chronic widespread pain, central sensitisation (CS) and mechanical allodynia. The predominant pathophysiology of pain in fibromyalgia is abnormal central pain processing or abnormal pain modulation processes. In our previous fMRI results suggest chronic pain may result from abnormal central pain processing: parts of medial and posterior thalamus, somatosensory cortices (S1/S2), insular cortical areas (posterior, mid, anterior insula), cingulate cortical areas (subgenual and pregenual anterior cingulate, anterior midcingulate, posterior cingulate), caudate/putamen and cerebellar areas. The purpose of neuroimaging in the current trial is to increase knowledge of the underlying neural mechanisms associated with chronic pain and how to manipulate them to treat chronic pain by targeting insomnia. Consistent with CATS, our functional MRI (fMRI) results suggest chronic pain may result from abnormal pain modulation processes. In our previous imaging work, results indicated aberrant pain processing seen in fibromyalgia is due to sustained arousal across common pain processing networks. Moreover, we identified treatment-related changes in neural activity...
among brain regions involved in the cognitive and affective dimensions of pain.32 41

Fibromyalgia is associated with grey matter atrophy in the amygdala, cingulate, insula, medial frontal cortex, parahippocampus and prefrontal cortex.19 42-44 Neuroimaging research has also associated chronic insomnia with reduced grey matter in the amygdala, orbitofrontal cortex and precuneus.15 46 Of particular interest, several studies have examined the Default Mode Network (DMN) and found both fibromyalgia47 48 and insomnia49 50 are characterised by heightened activity and connectivity patterns not typically observed in healthy persons. The present trial will be the first to examine CBT-I’s impact on the DMN in patients with fibromyalgia and comorbid insomnia.

The efficacy of CBT-I is well established. The vast majority (~70%–80%) of persons with insomnia treated behaviourally show sleep improvements that maintain through follow-ups up to 2 years, and patients rate behavioural techniques as more acceptable than sleep medications.17 Unlike sleep medications, behavioural approaches do not pose serious side effects and may be more cost-effective in the long run.51 A meta-analysis of non-pharmacological interventions for insomnia (all involved at least one component of CBT-I) in patients with chronic pain (11 RCTs, 3 involving fibromyalgia) found large sleep quality improvements and small-to-moderate pain reductions following treatment. Sleep quality effects were maintained at 1 year. To date, most CBT-I trials in patients with chronic pain52 have not required a specific minimum level of pain severity for inclusion. Thus, it is possible that individuals with low levels of pain were included in these trials and did not have high enough initial pain severity to show substantial improvement.

The proposed trial examines the novel hypothesis that sustained improvements in arousal, sleep and CS will result in sustained (or possibly enhanced) pain improvements over time. Currently, the long-term effects of CBT-I on clinical pain and its underlying neural mechanisms in fibromyalgia are unknown. The proposed trial offers the following methodological improvements: (1) recruitment of participants with more severe baseline pain, (2) expanded arousal outcomes (peripheral arousal, global cognitive arousal/stress, sleep-related and pain-related cognitive-affective factors), (3) imaging follow-ups at 6 and 12 months, (4) booster sessions (to ensure long-term maintenance of treatment effects), (5) a credible active control-sleep hygiene (SH) (to control for attentional/non-specific therapeutic effects) and (6) inclusion of moderation/mediation analyses. The proposed trial addresses key shortcomings in our current understanding of chronic pain.

Aims

The overarching goal of this randomised controlled trial is to study effects of CBT-I on objective and subjective measures of sleep, arousal and pain, as well as examine the temporal relationships between our hypothesised mediators (sleep and arousal) and pain. In our recent trial, CBT-I prompted larger initial improvements in sleep53 and CS54 than did cognitive behavioural treatment for pain. Given sleep and CS’s hypothesised mediating roles, we focus on CBT-I only here as the intervention. Additionally, given potential impact of non-specific therapeutic factors on outcomes, we compare CBT-I with an active and credible control condition, SH.

Our first specific aim is to examine the effects of 8 weeks of CBT-I relative to 8 weeks of SH control on arousal (HRV, cognitive-affective-dysfunctional sleep and pain cognitions, perceived global stress), subjective/objective sleep (SOL, wake after sleep onset (WASO), sleep efficiency and quality; insomnia impact) and pain after treatment and at 6 and 12 months follow-ups. We hypothesise that compared with SH, CBT-I will decrease arousal, improve sleep and decrease pain after treatment and at 6 and 12 months follow-ups. Our second specific aim is to examine CBT-I’s effect on resting state (RS) brain activity as well as neural activation patterns of functional brain networks and blood-oxygen-level dependent (BOLD) responses to painful stimuli in regions associated with pain processing. We hypothesise that compared with SH, CBT-I will reduce (normalise) RS brain activity in the DMN, which includes the cingulate cortex and medial prefrontal cortex, and reduce maladaptive pain-related brain network and BOLD activity in several regions associated with the cognitive and affective modulation of pain, including the inferior frontal gyrus, cingulate gyrus and insula. Our third specific aim is to study CBT-I’s long-term effect on structural characteristics of pain-related brain regions. We hypothesise that compared with SH, CBT-I will prompt structural changes indicative of a reversal of the maladaptive neural plasticity associated with chronic pain. Reversal will be characterised by increased grey matter volume/thickness, improved white matter integrity and stronger structural connectivity in the lateral-orbitofrontal and anterior/rostral cingulate regions, compared with the control following treatment and at both follow-ups. Finally, our fourth aim is to examine the mediating impact of arousal, sleep and CS on pain. We hypothesise that CBT-I will promote pain improvements through arousal reduction, sleep improvement and CS reversal. We hypothesise that significant improvements in all variables will be evident immediately following treatment, and that sustained improvements in arousal, sleep and CS will mediate sustained (and possibly increased) improvements in pain at 6 and 12 months. We will also evaluate whether these mediating effects explain unique variance of pain improvement over and beyond the mediating effects of global or possibly pain-specific and/or sleep-specific cognitive-affective factors.

METHODS

Trial design and study setting

Female patients (18 years of age and older) with fibromyalgia and chronic insomnia will be recruited from...
the University of Missouri in Columbia, Missouri, and surrounding area. Participants will be recruited through physician referral from Rheumatology, Internal Medicine and Sleep Clinics as well as community advertisements. Participants will be randomised to 8 weeks of CBT-I or SH. Both groups will receive four bimonthly phone booster sessions (B; figure 1). Baseline, post-treatment and 6 and 12 months follow-ups will measure sleep, arousal, neural plasticity and pain. All participants will sign written informed consent. Participants will be compensated US$150 following the baseline, post-treatment, 6 and 12 months follow-up assessments.

**Eligibility criteria**

Inclusion criteria are: (1) female, (2) 18+ years of age, (3) willing to be randomised, (4) can read and understand English, (5) diagnosed with fibromyalgia ((a) pain for 6+ months that is (b) confirmed by tender point test (with application of 4 kg force, participant reports for 6+ months that is (b) confirmed by tender point test, (c) baseline diaries indicate average pain intensity of ≥50/100) and insomnia ((a) insomnia complaints for 6+ months that (b) occur despite adequate opportunity and circumstances for sleep, (c) consist of one or more of the following: difficulty falling asleep, staying asleep or waking up too early, (d) daytime dysfunction (mood, cognitive, social, occupational) due to insomnia and (e) baseline diaries indicate >30 min of SOL or WASO on 6+ nights during the 2 weeks. Sleep diaries will be collected electronically via an online data management system (Qualtrics) with personal web-enabled devices or (if needed) study provided devices. Diagnosis of insomnia will be overseen by a sleep psychologist (CSMcC). Exclusion criteria are: (1) unable to provide informed consent, (2) cognitive impairment (Mini-Mental State Examination <26), (3) sleep disorder other than insomnia (ie, sleep apnoea (apnoea/hypopnea index >15), periodic limb movement disorder (myoclonus arousals per hour >15)), (4) bipolar or seizure disorder (due to risk of sleep restriction treatment), (5) other major psychopathology except depression or anxiety (eg, suicidal ideation/intent, psychotic disorders), (6) severe untreated psychiatric comorbidity (eg, schizophrenia, substance use disorder), (7) psychotropic or other medications (eg, beta-blockers) that alter pain or sleep, (8) participation in non-pharmacological treatment (including CBT) for pain, sleep or mood outside current trial, (9) internal metal objects or electrical devices and (10) pregnancy.

**Randomisation**

Biostatistician (CD) will select block size and perform randomisation. Other personnel (except for therapists and project coordinator) will be blinded to randomisation. Blocking guarantees balance, increases power and will be accounted for in analyses.

**Procedures**

**Screening**

Screening to assess fibromyalgia and insomnia symptoms and to rule out sleep disorders other than insomnia is carried out in four stages:

- Stage 1: brief screener (~10 min). The project coordinator will conduct a brief structured interview to address inclusion/exclusion criteria and establish probable fibromyalgia and insomnia diagnoses.
- Stage 2: clinical interview (~50 min). The assessor will: (1) conduct a semi-structured pain, sleep and psychiatric in-person interview, (2) perform tender point testing. Diagnosis of fibromyalgia will be overseen by a rheumatologist (CS).
- Stage 3: polysomnography (PSG; one overnight). One night of polysomnography will rule out sleep disorders other than insomnia (ie, apnoea, PLMD). The assessor will prepare participants for PSG in their own homes, and participants will sleep in their own beds. Referrals will be made for those disqualified to a neurologist (PS).
- Stage 4: sleep diary confirmation of insomnia (~5 min/day). Baseline sleep diaries will be used to confirm insomnia diagnosis and must show: >30 min of SOL or WASO on 6+ nights during the 2 weeks. Sleep diaries will be collected electronically via an online data management system (Qualtrics) with personal web-enabled devices or (if needed) study provided devices. Diagnosis of insomnia will be overseen by a sleep psychologist (CSMcC).

**Interventions**

Both interventions include 8 weekly, 50 min individual face-to-face sessions with a therapist (predoctoral graduate students in an APA accredited clinical or school psychology programme at the University of Missouri) and 4 bimonthly, 20 min phone booster sessions. SH will meet on the same schedule as CBT-I, controlling for therapist attention and other non-specific therapeutic factors. Session content for CBT-I and SH are provided in tables 1 and 2, respectively.

**Treatment integrity**

The three-step method by Lichstein et al will be used to measure treatment integrity.

**Treatment delivery/training**

Therapists will use manuals. Practice will begin with mock sessions and then recorded sessions with volunteers. The Principal Investigator (PI; CSMcC) will score all training.
sessions. Training will last ~16 weeks until therapists obtain mastery (scoring 100 on each session’s Treatment Delivery Score Sheet). For assessment of participant treatment delivery, all sessions will be recorded. Fifty per cent will be scored by consultant (registered psychologist). Senior consultant (registered psychologist) will double score initial 10 treatment and 10 booster sessions to establish fidelity, and 10% of remaining sessions for reliability. Consultants will inform the PI of scores <95% for supervisory/training purposes. The PI will review 25% and therapists will review 25% of each other’s sessions for ongoing training/supervision. Only consultant reviews will be used to assess fidelity.

**Treatment enactment**

To ensure home assignments are done, workbooks contain written instructions on home assignments. To assess enactment, participants will maintain daily electronic diaries and logs.

**Treatment credibility and expectancy**

At the end of session 3, participants will complete a treatment credibility questionnaire. This 4-item scale assesses the participant reaction to therapist and treatment efficacy, and participants provide ratings of 1 (strongly disagree) to 10 (strongly agree). Higher scores represent better treatment credibility. At the end of session 3 therapists will complete an expectancy for improvement scale.

**Outcomes**

A summary of study outcomes is provided in table 3 and a schedule of outcome measures is provided in table 4. A full description of the thermal pain task conducted...
Effect sizes in our prior trial that were small for pain \((f=0.2)\), medium to large for sleep \((f=0.31–0.39)\), large for imaging \((f=0.69–1.15)\), and large for pain-related and sleep-related cognitive-affective arousal \((f=0.69–1.15)\). To ensure adequate power with an active control, effect sizes from CBT-I trials in fibromyalgia with SH control groups were considered and ranged from small to medium for pain \((f=0.15–0.25)\); including pain-related anxiety and small to large for sleep outcomes \((f=0.15–0.40)\). Our prior trial did not measure peripheral arousal. However, based on prior research, small to medium effects \((f=0.15–0.25)\) are expected. We determined power based on the traditional repeated measures analysis of variance (RM ANOVA) approach, as there are no established procedures for accurate power estimation for multi-level modelling (MLM). Using G-Power\(^{58}\) for RM ANOVA within-between interaction, setting \(\alpha=0.05\), number of groups=2, number of measurements=4 and correlations between repeated measures=0.5, minimum statistical power=0.8, the sample size required to detect a small effect of \(f=0.15\) is 62. For the mediation model tested in aim 4, given that the effect sizes (ESs) of the mediating paths range from small to large \((f=0.15–0.40)\), a sample size of 130 provides sufficient power \((>0.8)\) to detect the mediation effects on pain.\(^{59}\)

### Missing values

Missing data will also be accounted for using MLM. This statistical procedure can handle missing data at all levels except the highest, which in our case, is level 2. When collecting measurements from the same people over time, some may not complete the study. Unlike RM ANOVA which would exclude these participants’ data from analysis, with MLM, their information is retained in the prediction model which increases statistical power. Additional steps will be followed: (1) group dropout rates will be compared using \(\chi^2\) analyses, (2) demographic and dependent variables will be examined for relationship to dropout, using related variables to impute missing values in analyses below (via SPSS Missing Items Analysis), (3) comparison of completers versus imputed analyses to further estimate dropout effects.

### Baseline demographics and participant characteristics

Group differences in baseline demographics and clinical characteristics will be analysed using independent sample t-tests for continuous variables (number of health conditions, body mass index, Mini-Mental State Examination, duration of fibromyalgia, duration of insomnia) and \(\chi^2\) analyses for categorical variables (sex, marital status, ethnicity, employment status, sleep or pain medication...
| Outcome category | Measure | Primary/Secondary | Details |
|------------------|---------|------------------|---------|
| Subjective sleep | Daily sleep diaries | Primary | Online diaries will be completed each morning (~5 min) during each 2-week assessment period and 8 weeks of treatment. Primary outcome variables include: sleep onset latency (time from initial lights-out until sleep onset), wake after sleep onset (time awake after initial sleep onset until last awakening), number of awakenings, total sleep time, sleep efficiency (total sleep time/time spent in bed ×100) and sleep quality rating (1—very poor to 5—excellent). Sleep and pain medication consumption variables will include: name, dosage and time taken. Sleep medication will be converted to number of lowest recommended dosage units,73 and pain medication to morphine equivalent dosage.73 |
| Insomnia Severity Index (ISI) | | Primary | At each time point, participants will complete the ISI (primary outcome).74 The ISI is a 7-item questionnaire that assesses the frequency and/or severity of insomnia symptoms (eg, “rate the current severity of your difficulty falling asleep”; choices range from 0 (none) to very severe (5)), as well as questions regarding the impact of insomnia on daytime functioning (eg, “to what extent do you consider your sleep problem to interfere with your daily functioning?”) (eg, daytime fatigue, mood, ability to function at work/daily chores, concentration, memory, mood, etc) currently; choices range from 0 (not interfering at all) to 5 (very much interfering). Total scores on the ISI range from 0 to 28, with higher scores representing more severe insomnia. |
| Objective sleep | Daily actigraphy | Secondary | Actiwatch 2 (Philips Respironics) is a watch-like device that monitors light and gross motor activity. Data will be analysed by proprietary software using 30 s epochs. A validated algorithm estimates the same variables (secondary outcomes) provided by diaries (except sleep quality). Participants wear the device 24/7 during each 2 weeks of assessment, and 8 weeks of treatment. |
| Polysomnographic (PSG) sleep | | Secondary | The Comet-PLUS Portable (Natus Neurology) Recording System will be used to conduct a single in-home overnight sleep study at baseline, post-treatment and both follow-ups. Consistent with ambulatory recommendations,75 monitoring consists of 10 electroencephalography, 2 EOG and 3 electromyography (EMG) (chin) using standard placements. It also includes respiratory inductance plethysmography (toracic/abdominal effort), oximeter (pulse/oxygen saturation), ECG, R/L anterior tibialis EMG, oral-nasal airflow thermocouple and nasal cannula pressure transducer. We require 4 hours of acceptable data (ie, scorable stage/respiratory events) and follow Sleep Heart Health Study76 procedures for training, data management and scoring. PSG provides sleep stage % (stage 1, 2, 3, rapid eye movement sleep) and absolute values for diary variables (secondary outcomes). |
| Arousal | Peripheral Arousal—heart rate variability (HRV) | Primary | Using Holter monitors, we will obtain 5 min ECG recordings during rest in a quiet controlled environment at each assessment. Time and spectral analysis of the short-term variability of heart rate (HR) will be performed using Pathfinder (SpaceLabs, Seattle, Washington) software to assess the neural regulation of HR. The time domain indices reflect the beat-to-beat variability with respect to time. The variables SD of the N-N intervals and the percentage of N-N intervals that exceed 50 ms will be examined. The frequency domain indices reflect the underlying rhythms of the mechanisms modulating HR. High frequency (0.15–0.4 Hz), low frequency (0.04–0.15 Hz) and very low frequency (below 0.04 Hz) spectral bands will be examined. |
| Global cognitive arousal—Perceived Stress Scale (PSS)77 | | Primary | The PSS (primary outcome) is a 10-item questionnaire that asks participants to appraise their stress level during the past month in response to several everyday situations (eg, “in the last month how often have you been able to control irritations in your life?”). Choices range from 0 (never) to 4 (very often). Higher total scores on the PSS indicate worse perceived stress. |
| Insomnia-specific cognitive-affective arousal—Dysfunctional Beliefs and Attitudes about Sleep (DBAS)* | | Primary | The DBAS78 is a 30-item scale that assess the degree to which an individual agrees with statements regarding sleep (eg, “Medication is probably the only solution to sleepiness”, “I need 8 hours of sleep to feel refreshed and function well during the day”). Participants rate their belief in each statement from 0 (strongly disagree) to 10 (strongly agree). Scores for each item are summed and higher scores on the DBAS indicate worse cognitive affective arousal related to insomnia. |

Continued
### Table 3  
Outcome category | Measure | Primary/Secondary | Details
--- | --- | --- | ---
**Pain** | Pain-specific cognitive-affective arousal-catastrophising—Pain Catastrophising Scale (PCS)\(^{78}\) | Primary | The PCS is a 13-item scale that measures the degree (from 0—not at all to 4—all the time) to which participants experienced certain thoughts or feelings during past painful events. Items are scored and total scores on the PCS represent worse pain catastrophising.

| | Daily clinical pain—Electronic Daily Diaries | Primary | On the daily electronic diaries, participants provide ratings on a 0–100 scale regarding their pain intensity (0—no pain sensation, 100—most intense pain imaginable) and pain unpleasantness (0—not at all unpleasant, 100—most unpleasant imaginable).

| | Subjective pain—McGill Pain Questionnaire (MPQ)\(^{79} 80\) | Secondary | The MPQ assesses participants pain symptoms across 21 categories. For each category, participants select the best word that described their pain. Qualitative responses are coded by numerical value (eg, 1–3 or 1–5), with higher values representing worse pain in that category. If they do not experience a specific category of pain, they do not provide a response to that category. Category scores are summed and total scores could range from 0 (no pain) to 78 (severe pain).

| | Patient-Centred Outcomes Questionnaire (PCOQ)\(^{81}\) | Secondary | The PCOQ is a 5-item questionnaire that assess on a 0-point to 10-point scale usual levels of pain, desired levels of pain, what level of improvement in treatment outcomes they would consider successful, what level of improvement in treatment outcomes they expect after treatment, importance of improvement in treatment outcomes.

| | Pain-related disability—Pain Disability Inventory (PDI)\(^{82} 83\) | Secondary | The PDI includes 7-item questionnaire rated on an 11-point scale (0=no disability, 10=total disability) indicating the degree to which chronic pain interferes with participant functioning in the following areas: family/home responsibilities, recreation, social activity, occupation, sexual behaviour, self-care and life-support activity. The seven ratings are summed to compute a total score (0–70), with higher scores indicating worse pain disability.

**Mood** | State Trait Anxiety Inventory (STAI)\(^{82}\) | Covariate | STAI asks respondents to rate how true 20 self-descriptive statements (eg, I feel calm) are on a 4-point scale (1=not at all, 4=very much so). Typically, respondents are asked to rate statements according to how they generally feel (trait-anxiety scale) and how they feel in the current moment (state-anxiety scale). Total scores range from 20 to 80, with higher scores indicating greater maladjustment.

| | Beck Depression Inventory—Second Edition (BDI-II)\(^{84}\) | Covariate | The BDI-II contains 21 items that measure the severity of depressive symptomatology on a 3-point scale (0=absence of symptoms, 3=most severe). Typically, respondents answer for the previous week, but the previous 2 weeks were used in this study to match the 2-week activity recording period for each assessment. Total scores range from 0 to 63. Ranges for clinical levels of depression are 0–13 (minimal), 14–19 (mild), 20–28 (moderate) and 29–63 (severe).

| | Pain Anxiety Symptoms Scale (PASS-20)\(^{86}\) | Covariate | The PASS measures fear and anxiety responses related to pain. The PASS-20 revised short form version contains 20 items in which participants must rate the frequency in which they experience fearful and anxiety ridden responses related to pain or pain-related situations. This scale is widely used in clinical screening of chronic pain and pain research.

| | Anxiety and Preoccupation about Sleep Questionnaire (APSQ)\(^{87}\) | Covariate | The APSQ measures the intensity of both daytime and nighttime worry related to insomnia. Participants are presented with 10 statements describing several sleep related worries and participants are asked to indicate how true they are on a scale from 0 (not true) to 10 (very true). Scores on this scale are associated with self-reported (eg, diary) sleep measures as well as daytime impairment, with higher scores representing worse anxiety related to sleep.

Continued
Evaluations of aims

**Testing of aim 1**

To examine the effects of CBT-I on arousal, sleep and pain in patients with fibromyalgia and insomnia, we will use a 2-level MLM. The first level will be the repeated measure over time nested within the second level which is the person-level data. Group (CBT-I, SH) will capture the between-subjects variability, while time (baseline, post-treatment, 6 months, 12 months) will capture within-subject variability. Based on a priori hypotheses, separate MLMs will be conducted for each sleep, arousal and pain usage). Any variables that are significantly different between groups will be entered in all analyses. We will also include age and education in all analyses as necessary.

### Table 3

| Outcome category | Measure                                      | Primary/Secondary | Details                                                                                                                                                                                                 |
|------------------|----------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Neuroimaging     | Neural plasticity and central sensitisation | Primary           | Three imaging protocols 1) structural MRI (MPRAGE), 2) functional MRI (EPI blood-oxygen-level dependent) and 3) diffusion-weighted imaging (DWI), will assess neural plasticity and central sensitisation. Image acquisition data will be acquired with Siemens’ new MAGNETOM Vida 3T and a 20-channel head-neck coil. The parameters for the 3D-T1-weighted structural scans are: 256 axial slices (0.90×0.89×0.89 mm³; TR=0.75 s, TE=0.0045 s, flip angle=75°, matrix=256×256, FOV=256 mm. T2-gradient EPI sequence for the resting state and fMRI scans will use the following parameters: whole brain, 36-contiguous slices (axial), 3 mm³ isotropic voxels, oriented parallel to the AC-PC plane, TR=2.46 s; TE=30 ms; flip angle=90°; 76×76 matrix and 120 volumes. The parameters for the diffusion-weighted scans are: 32 slices, 1×1×3.25 mm³, TR=3.6 s, TE=0.064 s, flip angle=90°, directions=6. The sequence of scan acquisition is: Localizer, gradient field map, 3D anat, resting state (x2, −5 min), fMRI experimental pain scans (x3, −25 min), DWI (−12 min). During the resting state scans, subjects are told to relax, limit movement and try not to fall asleep. In preparation for the experimental pain scan, participants will first undergo quantiative sensory testing (QST) calibration trials outside of the scanner, in order to determine individual pain tolerance and to ensure that experienced pain intensity is equal in both treatment groups at baseline. A computer-controlled Medoc Pain and Sensory Evaluation System (Pathway Model ATS, Medoc Advanced Medical Systems, Durham, North Carolina) will be used to deliver thermal stimuli. QST calibration uses a series of calibration trials (CTs), to identify their pain tolerance temperature, which will be used during their experimental pain scanning session. The CTs start at 43°C and increase by 1°C until their tolerance, or 51°C is reached, whichever comes first. Subjects will sit in a chair, remove their shoes and socks and extend their feet outward. A researcher will wipe the bottom of their foot with an alcohol pad, after which a contact heat thermode will be placed on the plantar surface of the foot. Each stimulus cycle is initiated by the experimenter via key press. After each stimulus, subjects will describe the sensation (pain/not painful) and rate its pain intensity on a scale from 0—no pain to 100—worst pain imaginable. Once the ratings and interstimulus interval have finished, the cycle will be repeated until their tolerance temperature is identified (ie, the lowest temperature with a pain intensity rating of ≥65). This will be the temperature that will be used during their scanning sessions. During each 5 min experimental pain scan, thermal stimuli will be delivered with an MR compatible, computer-controlled, CHEPS Pathway system, which is a peltier-element-based stimulator, and is capable of producing stimuli across a range of temperatures (33°C–51°C). The start of each scan will begin with the thermode at ambient temperature for 30 s and then 16 cycles of the following: 12 s at ambient temperature, then in <2 s the temperature will steadily increase (ramp) until reaching their pain temperature (determined by the calibration trials), and remain at that temperature (hold) for 5 s, followed by a variable inter stimulus interval of 12–20 s. Following the 16th cycle, the scan proceeds for another 30 s with the thermode at ambient temperature.

*Given that our previous clinical trial evaluating CBT-I relative to a waitlist control on sleep and pain and arousal outcomes found large effect sizes for CBT-I-related improvement in DBAS-assessed cognitive-affective arousal related to sleep, we used the same measure in this trial as well. However, another important index of presleep arousal (including somatic and cognitive arousal) could be captured by using the Pre-Sleep Arousal Scale (PSAS). Thus, we will consider using the PSAS in future trials.

AC-PC, anterior commissure-posterior commissure; DWI, diffusion weighted imaging; EOG, electrooculography; EPI, echo planar imaging; ET, echo time; FOV, field of view; TR, repetition time.
outcome. Planned contrasts will be conducted consistent with a priori hypotheses. Bonferroni-adjusted p values will control family-wise error (FWE). Using an MLM approach allows us to compare group means like in a RM ANOVA, and make comparisons at the individual level. Using an MLM approach, we can answer questions such as: do participants differ at specific time points on the outcome in terms of treatment, do slopes differ in terms of treatment or across participants, do specific time points vary among individuals. MLM allows for comparison of individual trajectories and comparisons between participants.

Clinical significance will also be evaluated for insomnia and pain intensity. Because there are no established clinical significance guidelines for insomnia, participants will be classified as no longer meeting trial criteria for difficulties initiating and maintaining sleep (ie, self-reported SOL or WASO >30 min on 3 or more days out of 14) at post-treatment, 6 months follow-up and 12 months follow-up. We will also compare responders (those who no longer meet criteria for insomnia) versus non-responders (those who still meet criteria for insomnia) on all outcomes using independent sample t-tests. In terms of pain, participants will be classified as moderated and substantially improved (pain intensity decreases of 30% and 50%, respectively) based on provisional benchmarks recommended for determining clinically important differences in pain intensity in clinical trials by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials Consensus Panel.60 These improvement benchmarks will be examined for both morning and evening pain intensity. Group differences will analysed using $\chi^2$ test.

**Testing of aim 2**

**Resting state**

To better understand the effects of treatment on basal brain activity, we will characterise the changes in RS data associated with behavioural changes over time. Towards this end, we will use Group ICA of fMRI Toolbox (GIFT) to perform independent component analyses (ICA) of the RS data. This procedure will decompose the data into discrete components, each representing the unique time course of the brain regions associated with that component (ie, a unique spatial-temporal map). This analytic approach will allow us to identify common (across all groups) and group-specific temporal-spatial ICAs representing the DMN, its subnetworks, pain-related networks, those involved with affective processing and others (eg, sensorimotor networks, saliency network, frontoparietal executive networks, etc). Once identified, GIFT will then be used to test for changes in the effective connectivity and functional coherence among these networks and

| Table 4  Schedule of outcome measures |
|--------------------------------------|
| **Assessment period** | **Base** | **Tx** | **Post** | **Boosters** | **FUs** |
| **Weeks** | 2 | 8 | 2 | 2 | 2 |
| Telephone and clinical interviews, consent, MMSE | X |
| Actigraph, PSG, ISI, MPQ, PDI, RH, Wind-Up, HRV, DBAS, PSS, PCS, STAI, BDII, PASS-20, APSQ | X | X | X |
| Electronic daily diaries | X | X | X | X | X |
| Tx integrity—delivery and receipt, treatment credibility | X |

**Table 5  Study timeline**

| Project year → | 1 | 2 | 3 | 4 | 5 |
|----------------|---|---|---|---|---|
| **Half →** | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 |
| 1. Develop manual of operating procedures. Register with clinicaltrials.gov. Publish trial protocol. Develop SH. Train therapists and assessor. | | | | | |
| 2. Recruit, collect baseline, deliver treatment | | | | | |
| 3. Collect post-treatment assessment | | | | | |
| 4. Collect 6 and 12 months follow-up assessments | | | | | |
| 5. Offer/Provide CBT-I to SH controls | | | | | |
| 6. Final data analysis and dissemination (continues after grant ends); final report | | | | | |

CBT-I, cognitive behavioural treatment for insomnia; SH, sleep hygiene.
their component brain regions. Then the influence of covariates can then be added to the analyses to examine their influence on specific nodes and overall functional coherence of the network. We will also compare the component representative of the DMN (ie, a specific spatial-temporal map) from each group with a study-specific DMN map to calculate group-specific differences. By comparing these differences with a standardised DMN template (of healthy controls that is included in GIFT), we can make statistical inferences about group-related differences and treatment-related changes over time. Although the standardised template of the DMN included with GIFT is widely used, we acknowledge the limitations of using this template because it is based on healthy individuals.61 However, the fact that this template is based on a healthy population, valid inferences about deviations from a normal DMN in a clinical population are possible.

Using the approach outlined above, we anticipate that the component best representing the DMN in both groups will include most, if not all of the following Brodmann areas: BA 11—orbitofrontal area (orbital and rectus gyrus), BA 32—dorsal anterior cingulate cortex, BA 9—dorsolateral prefrontal cortex, BA 10—anterior prefrontal cortex (most rostral part of superior and middle frontal gyri), BA 47—orbital part of inferior frontal gyrus, BAs 23 and 31 the ventral and dorsal aspects of the posterior cingulate cortex, BA 39—angular gyrus, BA 40—supramarginal gyrus, BA 37—fusiform gyrus and BAs 30 and 36 of the parahippocampal gyrus. Because participants have chronic pain we expect overlapping pain-related regions to be included (eg, BAs 40, 30, 31). However, given the tonic nature of chronic pain, we expect the DMN might also involve additional pain-related brain regions such as: BAs 4—primary motor cortex, 6—premotor cortex, 16—insular cortex, and 46—dorsolateral prefrontal cortex.

Functional MRI

Using a flexible analytical approach involving MLM and random effects general linear models, we will test for group differences in reported pain and associated pain-related patterns of activity and how those results vary as a function of treatment response and time. To clarify treatment-related changes to painful stimuli, we will identify brain regions of interest (ROIs) wherein the stimuli are significantly convolved with a haemodynamic response function (HRF). When identifying potential ROIs, a combination of criteria are used to guard against type I errors. These criteria are: (A) p value ≤0.05, using the false discovery rate and FWE corrections; (B) a spatial extent of 50+ contiguous voxels and a minimum volume of 100 µL and (C) the centre of mass gravity/peak voxel in a targeted region. Because all of the imaging data will be in standardised MNI (Montreal Neurological Institute) space, the coordinates of targeted regions will be checked against the standardised Wake Forest Pick Atlas. The combination of these criteria establish an image-wise p value of 0.00002 and an effective pixel-wise alpha of p≤0.0002.62 This approach will allow us to include additional criteria such as small volume corrections during analyses which may also include area under the curve, growth curve modelling and cluster analyses may also be used to test for group-related differences, over time, in HRF characteristics relative to treatment response and the predictive ability of outcome measures. With the aforementioned analytical approach, we anticipate to identify pain-related activity among typical pain-related brain regions such as: the thalamus, supplementary motor area, primary and secondary somatosensory cortices, anterior and posterior insula, dorsal anterior cingulate cortex and the dorsolateral prefrontal cortex. We hypothesise that these, and other pain-related, regions will be identified at baseline, and that they will be sensitive to treatment effects and changes in other behavioural outcome measures (eg, sleep measures, pain, arousal, etc) over time.

Testing of aim 3

Structural MRI

To study CBT-I’s long-term effect on structural characteristics of pain-related brain regions, we will use the FSL tissue segmentation pipeline for analysis of cortical ribbon changes. The FreeSurfer Longitudinal Processing pipeline is highly specialised to provide unbiased results about longitudinal changes using common and within-subject templates, allowing for significant increases in reliability and statistical power.63 The pipeline accounts for inherent autocorrelations in the data due to repeated sampling allowing us to assess changes among outcome measures (eg, arousal, sleep, pain and grey matter thickness, in ROIs) within/between groups at each interval and longitudinally. Based on the literature39 40 64–67 and our previous results, we anticipate finding significant differences between the CBT-I and SH groups among the somatosensory cortices, cingulate cortices (anterior, mid-dorsal), dorsolateral prefrontal cortex, frontal gyr (superior, middle, inferior), insula (anterior, posterior), temporal gyri, thalamus and periaqueductal grey and their relationship to additional outcome variables. Other behavioural and/or outcome measures refers to possibility of using any other information collected about the participants (eg, sleep measures, pain, arousal, etc).

Diffusion weighted imaging

The diffusion weighted images (DWI) will be processed via FMRIB’s Diffusion Toolbox (FDT) to examine white matter characteristics DWI. DWI measures the diffusion of water across cell membranes in three-dimensional. Because of this, the directionality of the diffusion (anisotropy) can be determined. The FDT pipeline will estimate the apparent diffusion coefficient (ADC—amount of diffusion possible independent of direction) and fractional anisotropy (FA—an index 0 (isotropic diffusion)–1 (diffusion along one vector)) at the individual and group levels. Higher values of FA and reduced ADC represent increased complexity of brain tissue.68 69 Higher values of FA and reduced ADC represent increased complexity of
brain tissue. We will map white matter tracts and model connections among brain regions with probabilistic tractography. As this will be a novel contribution to the field, we anticipate potential changes for CBT-I but not SH in FA and ADC along the prefronto-subcortical dorsolateral-prefrontal and anterior cingulate-prefrontal pathways.

Testing of aim 4

Finally, to examine the mediating impact of arousal, sleep, and CS on the effects of CBT-I on pain (aim 4), we will use 4-wave cross-lagged path analysis. Controlling for baseline, autoregressions and reciprocal effects among sleep, arousal (HRV, cognitive arousal, stress) and CS (neural factors), we will examine whether CBT-I continues to predict improved sleep and decreased arousal and CS at 6 months, and then predicts pain at 12 months. Mediation effects of arousal, CS and improved sleep of impact of CBT-I on pain outcomes at 12 months will be estimated. We will evaluate whether mediation effects remain significant after controlling for global and pain-specific and sleep-specific cognitive-affective variables.

Patient and public involvement

Patients and public are not involved in any of the following study procedures: development of research questions and outcome measures, study design, participant recruitment, plan for results dissemination, assessment of burden of intervention.

ETHICS AND DISSEMINATION

All study procedures were approved by the Institutional Review Board at the University of Missouri on 11 July 2018. An independent four-member Safety Monitoring Committee (SMC) was assembled in January 2019 to oversee the study. Members include those with expertise in fibromyalgia, chronic insomnia, sleep medicine and CBT. All SMC members attested that they have no conflicts of interest. The SMC met once via conference call at the beginning of the study to review the study protocol, Manual of Operating Procedures, Informed Consent Form and monitoring plan with emphasis on data integrity and patient safety issues. Following this initial meeting, the SMC will meet every 6 months to review progress reports prepared by the team biostatistician. Those SMC reports will include interim statistical analyses. Any changes to these procedures that are recommended by the SMC will be adopted. The SMC will review adverse events and monitor study results, focusing on efficacy, recruitment progress, randomisation, compliance, retention, protocol adherence, operating procedures, forms completion, intervention effects, participant safety and minority inclusion. The PI will also submit annual reports to the funding agency.

Results from this trial will be presenting at national conferences, including the Associated Professional Sleep Societies (or SLEEP) and the American Pain Society, in the final year of the project. Dissemination will also occur through the submission of a primary article on the outcomes, a second article focusing on the functional neural changes (ie, RS and fMRI results), a third article focusing on the structural neural changes and a fourth focusing on outcome mediation. The treatment materials will be shared electronically and will be widely available to clinicians.

Acknowledgements

The authors would like to thank the ongoing contributions and support from study participants, study staff (research assistants, study coordinator and other site staff) responsible for trial setup, participant recruitment, data collection and data management.

Contributors

All authors made substantial contributions to the concept and design of the study. CM drafted initial protocol, with input from all authors. JC, RS, MR drafted MRI protocol. CD drafted statistical analysis plan. CM, PS and CS drafted screening procedures. CM and AFC drafted the manuscript. All authors revised the manuscript.

Funding

This work is supported by the National Institute of Nursing Research (NINR) at the National Institute of Health (NIH), grant number NR017168.

Disclaimer

The study sponsor was not actively responsible or involved in the study design and will have no involvement in collection, management, analysis or interpretation of data. The sponsor will have no involvement in future manuscript preparation and decision to submit for publication. This research was done without patient involvement. Patients were not invited to comment on the study design and were not consulted to develop patient relevant outcomes. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication

Not required.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Christina S McCrae http://orcid.org/0000-0003-4313-686
Ashley F Curtis http://orcid.org/0000-0002-2311-5674

REFERENCES

1. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain 2012;13:715–24.
2. Andersson HI, Ejlertsson G, Leden I, et al. Impact of chronic pain on health care seeking, self care, and medication. results from a population-based Swedish study. J Epidemiol Community Health 1999;53:503–9.
61 Franco AR, Pritchard A, Calhoun VD, et al. Interrater and intermethod reliability of default mode network selection. Hum Brain Mapp 2009;30:2933–303.
62 Forman SD, Cohen JD, Fitzgerald M, et al. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med 1995;33:636–47.
63 Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402–18.
64 Vatthauer KE, Craggs JG, Robinson ME, et al. Sleep is associated with task-negative brain activity in fibromyalgia participants with comorbid chronic insomnia. J Pain Res 2015;8:819.
65 McCrae CS, et al. BMJ Open 2020;10:e033760. doi:10.1136/bmjopen-2019-033760
66 Franco AR, Pritchard A, Calhoun VD, et al. Improving the reporting of within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402–18.
67 Reuter M, Schmansky NJ, Rosas HD, et al. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402–18.
68 McCrae CS, et al. BMJ Open 2020;10:e033760. doi:10.1136/bmjopen-2019-033760
69 Boissoneault J, Vatthauer KE, Craggs JG, Robinson ME, et al. Low-to-moderate alcohol consumption is associated with hippocampal volume in fibromyalgia and insomnia. Behav Sleep Med 2017;15:438–50.
70 Boissoneault J, Vatthauer KE, Craggs JG, Robinson ME, et al. Low-to-moderate alcohol consumption is associated with hippocampal volume in fibromyalgia and insomnia. Behav Sleep Med 2017;15:438–50.
71 Behrens TEJ, Berg HJ, Jbabdi S, et al. Probabilistic diffusion tractography with multiple fibre orientations: what can we gain? Neuroimage 2007;34:144–55.
72 Behrens TEJ, Johansen-Berg H, Woolrich MW, et al. Non-Invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003;6:750–7.
73 Behrens TEJ, Woolrich MW, Jenkinson M, et al. Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med 2003;50:1077–88.
74 Behrens TEJ, Woolrich MW, Jenkinson M, et al. Characterization and propagation of uncertainty in diffusion-weighted MR imaging. Magn Reson Med 2003;50:1077–88.
75 Duerden EG, Albanese M-C. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. Hum Brain Mapp 2013;34:109–49.
76 Duerden EG, Albanese M-C. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. Hum Brain Mapp 2013;34:109–49.
77 Lichtstein KL, Nau SD, Wilson NM, et al. Psychological treatment of hypnotic-dependent insomnia in a primarily older adult sample. Behav Res Ther 2013;51:787–96.
78 Svendsen K, Borchgrevink P, Fredheim O, et al. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med 2011;25:725–32.
79 Morin CM. Insomnia: psychological assessment and management. Guilford Press, 1993.
80 Redline S, Sanders MH, Lind BK, Smith Philip L, Kiley James P, et al. Methods for obtaining and analyzing unattended polysomnography data for a multicenter study, sleep heart health research Group. Sleep 1998;21:759–67.
81 Silva GE, Goodwin JL, Sherrill DL, et al. Relationship between reported and measured sleep times: the sleep heart health study (SHHS). J Clin Sleep Med 2007;3:622–30.
82 Cohen S, Kamarck T, Mermelstein R. Perceived stress scale. In: Measuring stress: a guide for health and social scientists, 1994.
83 Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale. In: Measuring stress: a guide for health and social scientists, 1994.
84 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
85 Beck AT, Steer RA, Garbin MG. Beck depression inventory. 2 edn. San Antonio, TX: The Psychological Corporation, 1996.
86 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
87 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
88 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
89 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
90 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
91 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
92 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
93 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
94 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
95 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
96 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
97 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
98 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
99 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.
100 Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory. Form Y. Palo Alto, CA: Consulting Psychologists Press, 1983.